Dr Daniel Ford is a consultant clinical oncologist with over 13 years of experience, specialising in the treatment of prostate, bladder, and kidney cancers. He is based at The Harborne Hospital, part of HCA Healthcare UK in Birmingham, and also sees patients at GenesisCare centres in Birmingham and Oxford. Dr Ford is a specialist advisor in uro-oncology at GenesisCare, contributing to the development of innovative treatment protocols such as 5-day radiotherapy for prostate cancer, re-irradiation for recurrent prostate cancer, and renal stereotactic ablative radiotherapy (SABR).

He is actively involved in cancer research and serves as the deputy clinical cancer lead for the West Midlands NIHR Clinical Research Network, supporting and promoting research activities across the region. Dr Ford leads the local arm of the PACE trial, which investigates profound hypofractionation techniques for localised prostate cancer. He has also played a key role in advancing SABR, a precision radiotherapy technique originally developed for brain and lung cancers, now applied to metastatic prostate cancer.

Dr Ford's expertise encompasses a range of oncological treatments, including hormonal therapies, chemotherapy, immunotherapy, radiotherapy, MRIdian MR linac advanced radiotherapy, and prostate brachytherapy. He is experienced in providing and evaluating all oncological treatments for prostate, kidney, and bladder cancers.

He is a member of professional bodies such as the Royal College of Radiologists, the General Medical Council, and the British Medical Association. Dr Ford is committed to delivering high-quality, patient-centred care and continues to contribute to the advancement of oncological treatments through his clinical and research work.